Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination

Overview

The objective of this study is to study immune memory generated against the yellow fever (YFV) vaccine in participants who have previously received the vaccine. Volunteers will not receive vaccine shots; only immune responses to previous yellow fever vaccination will be studied. The study involves one or multiple blood draws.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: December 2025

Detailed Description

The goal of this study is to characterize immune memory in humans who have previously received yellow fever vaccine. The project is designed to study the magnitude and persistence of both humoral, and cell-mediated immune memory generated post-vaccination. Since aging has an effect on the immune system (eg. decreased thymic output, replacement of hematopoietic cells in the bone marrow with adipocytes), the researchers will analyze the young adults (aged 18-45 years) and the older vaccinees (55 years or older) in separate groups. The specific aims of the study are to: – Determine the phenotypic and functional characterization of memory T cell responses to yellow fever vaccination – Determine neutralizing antibody titer after yellow fever vaccination

Arms, Groups and Cohorts

  • Group 1: 18 to 45 years of age
    • Between the ages of 18 and 45 at the time of yellow fever vaccination
  • Group 2: 55 years of age and above
    • Aged 55 or greater at the time of yellow fever vaccination

Clinical Trial Outcome Measures

Primary Measures

  • Determine the phenotypic and functional characterization of memory T cell responses to YF vaccination
    • Time Frame: Immune responses will be measured from at least 30 days after yellow fever vaccination.
    • This is an exploratory analysis of variation in immune response with time since last yellow fever virus vaccination.

Participating in This Clinical Trial

Inclusion Criteria

  • Able to understand and give informed consent – Age 18-45 years (Group 1) or 55 years and above (Group 2) at the time of yellow fever vaccination – Documentation (international certificate of vaccination (yellow card) or medical record) indicating receipt of yellow fever vaccine. Exclusion Criteria:

  • Recipient of any vaccines within 30 days before the study visit (not applicable to older adults) – History of a progressive and severe chronic medical condition resulting in impaired immunity (such as diabetes, kidney or liver dysfunction) – Required use of immunosuppressive medications – Reporting HIV, Hepatitis B (surface antigen positive) or Hepatitis C infections (antibody positive) on the medical/health history form – Recipient of a blood product or immune globulin product within 42 days of study visit – Reporting pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Emory University
  • Collaborator
    • National Institute of Allergy and Infectious Diseases (NIAID)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Sri Edupuganti, MD MPH, Assistant Professor – Emory University
  • Overall Official(s)
    • Rafi Ahmed, PhD, Study Chair, Emory University
    • Srilatha Edupuganti, MD, Principal Investigator, Emory University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.